SanBio Company Limited

TSE:4592 Stock Report

Market Cap: JP¥71.0b

SanBio Valuation

Is 4592 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4592 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4592's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4592's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4592?

Other financial metrics that can be useful for relative valuation.

4592 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-22.7x
PEG Ration/a

Price to Book Ratio vs Peers

How does 4592's PB Ratio compare to its peers?

The above table shows the PB ratio for 4592 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
4894 Cuorips
9.7xn/aJP¥58.1b
4974 Takara Bio
1.1x30.2%JP¥126.6b
2160 GNI Group
4x18.9%JP¥149.0b
2929 Pharma Foods International
2.4xn/aJP¥27.2b
4592 SanBio
45.2x15.0%JP¥71.0b

Price-To-Book vs Peers: 4592 is expensive based on its Price-To-Book Ratio (45.2x) compared to the peer average (4.3x).

Price to Earnings Ratio vs Industry

How does 4592's PE Ratio compare vs other companies in the JP Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
 n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
 n/an/an/a
No more companies

Price-To-Book vs Industry: 4592 is expensive based on its Price-To-Book Ratio (45.2x) compared to the JP Biotechs industry average (3.6x).

Price to Book Ratio vs Fair Ratio

What is 4592's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4592 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio45.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 4592's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4592 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,034.00
JP¥1,130.00
+9.3%
70.3%JP¥2,500.00JP¥270.00n/a5
Oct ’25JP¥1,315.00
JP¥1,130.00
-14.1%
70.3%JP¥2,500.00JP¥270.00n/a5
Sep ’25JP¥1,046.00
JP¥1,130.00
+8.0%
70.3%JP¥2,500.00JP¥270.00n/a5
Aug ’25JP¥1,110.00
JP¥1,130.00
+1.8%
70.3%JP¥2,500.00JP¥270.00n/a5
Jul ’25JP¥1,218.00
JP¥960.00
-21.2%
85.4%JP¥2,500.00JP¥270.00n/a5
Jun ’25JP¥506.00
JP¥800.00
+58.1%
94.3%JP¥2,300.00JP¥270.00n/a5
May ’25JP¥420.00
JP¥800.00
+90.5%
94.3%JP¥2,300.00JP¥270.00n/a5
Apr ’25JP¥439.00
JP¥954.00
+117.3%
77.8%JP¥2,300.00JP¥270.00n/a5
Mar ’25JP¥770.00
JP¥1,742.00
+126.2%
54.5%JP¥3,100.00JP¥310.00n/a5
Feb ’25JP¥549.00
JP¥1,742.00
+217.3%
54.5%JP¥3,100.00JP¥310.00n/a5
Jan ’25JP¥702.00
JP¥1,742.00
+148.1%
54.5%JP¥3,100.00JP¥310.00n/a5
Dec ’24JP¥505.00
JP¥1,782.00
+252.9%
56.6%JP¥3,300.00JP¥310.00n/a5
Nov ’24JP¥417.00
JP¥1,782.00
+327.3%
56.6%JP¥3,300.00JP¥310.00JP¥1,013.005
Oct ’24JP¥626.00
JP¥1,804.00
+188.2%
54.1%JP¥3,300.00JP¥420.00JP¥1,315.005
Sep ’24JP¥619.00
JP¥1,804.00
+191.4%
54.1%JP¥3,300.00JP¥420.00JP¥1,046.005
Aug ’24JP¥615.00
JP¥1,824.00
+196.6%
55.2%JP¥3,400.00JP¥420.00JP¥1,110.005
Jul ’24JP¥612.00
JP¥1,850.00
+202.3%
52.5%JP¥3,400.00JP¥550.00JP¥1,218.005
Jun ’24JP¥668.00
JP¥1,942.00
+190.7%
53.0%JP¥3,400.00JP¥550.00JP¥506.005
May ’24JP¥621.00
JP¥2,022.00
+225.6%
51.0%JP¥3,400.00JP¥550.00JP¥420.005
Apr ’24JP¥686.00
JP¥2,022.00
+194.8%
51.0%JP¥3,400.00JP¥550.00JP¥439.005
Mar ’24JP¥680.00
JP¥2,082.00
+206.2%
53.6%JP¥3,700.00JP¥550.00JP¥770.005
Feb ’24JP¥782.00
JP¥2,192.00
+180.3%
44.6%JP¥3,700.00JP¥1,100.00JP¥549.005
Jan ’24JP¥788.00
JP¥2,192.00
+178.2%
44.6%JP¥3,700.00JP¥1,100.00JP¥702.005
Dec ’23JP¥799.00
JP¥2,192.00
+174.3%
44.6%JP¥3,700.00JP¥1,100.00JP¥505.005
Nov ’23JP¥826.00
JP¥2,272.00
+175.1%
48.6%JP¥4,100.00JP¥1,100.00JP¥417.005

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y